DEADLINE APPROACHING: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / September 18, 2017 / Khang & Khang LLP (the ”Firm”) announces a securities class action lawsuit against IntelliPharmaCeutics International Inc. (”IntelliPharmaCeutics” or the ”Company”) (NASDAQ: IPCI). Investors who purchased or otherwise acquired IntelliPharmaCeutics shares from January 14, 2016 through July 26, 2017, inclusive (the ”Class Period”), are encouraged to contact the Firm before the September 29, 2017 lead plaintiff motion deadline.

If you purchased IntelliPharmaCeutics shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.

According to the Complaint, throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its New Drug Application (”NDA”) for Rexista; that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting enough data to support approval of the NDA; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.

On July 24, 2017, scientists from the U.S. Food and Drug Administration (”FDA”) expressed concerns that the Company failed to provide enough data about the abuse potential of Rexista. On July 26, 2017, IntelliPharmaCeutics announced that two advisory committees of the FDA voted 22 to 1 to oppose the Company’s NDA for Rexista, citing insufficient data about the abuse-deterrent properties of the drug as a motivating concern. Upon release of this news, the Company’s share price lowered materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may be considered Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 475728